Company attributes
Other attributes
Deep Genomics is a medical company focused on developing genetic therapies. It builds artificial intelligence-driven platforms that guide the creation of new medical therapies by blending synthetic biology, artificial intelligence and genetic medicine.
Brendan Frey, Andrew Delong, Hannes Bretschneider and Hui Yuan Xiong founded Deep Genomics in 2015 in Toronto, Ontario, Canada. It has a growing team of geneticists, molecular biologists and chemists from University of Cambridge, Massachusetts Institute of Technology (MIT), Stanford University, University of Toronto, University of California, San Diego, University of Washington and University of Waterloo. It is funded by primarily by Bay Area investors and aims to develop new ways of detecting and treating disease using biologically accurate artificial intelligence technology.
Deep Genomics uses neural networks to analyze genomic data, allowing scientists to identify the genes that cause diseases and develop drugs that deal with them. It has also specialized in finding elusive and less direct disease triggers in a person’s genome. Deep learning can identify patterns in DNA that might contribute to diseases such as spinal muscular atrophy and nonpolyposis colorectal cancer
CEO of Deep Genomics Brendan Frey — Deep Genomics: Changing the Course of Genomic Medicine
Project Saturn is the name of Deep Genomics artificially intelligent drug prediction and design platform. The project is analyzing over 69 billion oligonucleotides against 1 million gene targets and narrowing down their results to produce 1000 potential new compounds that will work to have the predicted biological affect. The platform is able to continuously improve its predictions in a closed loop based on its failures and successes in reference to human cells. The system is designed to predict what affect an antisense oligonucleotide compound (AGO) on human cells, taking into account individual genotype and multiple biological mechanisms.
On November 18th, 2015 raised $3,700,000 in seed funding from True Ventures, Bloomberg Beta, and 11.2 Capital.
After completing its series A funding round on September 25th, 2017, Deep Genomics raised $13,000,000 in funding from Khosla Ventures and True Ventures.
Deep Genomics announced that it will begin working with Wave Life Sciences on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease on April 10th, 2018. Deep Genomics will be offering Wave Life Sciences access to their machine learning platforms to help increase the efficiency of developing new therapies for treating genetic neuromuscular disorders. The two companies will be collaborating to identify therapeutic oligonucleotides that act on gene targets which reduce the negative effects of genes causing neuromuscular disease.
